Mustang Bio
NASDAQ: MBIOWorcester, US · Delaware corporation · 42 employees on LinkedIn · 1 known investors
Mustang Bio in-licenses and develops next-generation therapies aimed at treating patients, operating in the biotechnology and therapeutics sector.
Founders & leadership
MW
Michael WeissExecutive
ML
Manuel LitchmanPresident, Chief Executive Officer and Director
GF
Greg FurrowChief Quality Officer
Board
LA
Lindsay A. RosenwaldBoard director
NH
Neil HerskowitzBoard director
Investors · 1
Reported raises · per SEC filings
Form D private placements$102.3M disclosed across 4 rounds · 2017–2024
▶$2.5MraisedJun 2024 · 1 investors · BiotechnologyRule 506(b)
▶$2.5MraisedJun 2024 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Manuel B. Litchman, M.D.Executive Officer, Director
- Adam J. ChillDirector
- Michael Zelefsky, M.D.Director
- James B MurphyExecutive Officer
- Neil HerskowitzDirector
- Lindsay A. Rosenwald, M.D.Director
- Michael S. WeissDirector
- Offering amount
- $2.5M
- Amount sold
- $2.5M
- Sales commissions
- $175.9K
- Placement agents
- H.C. Wainwright & Co., LLC
- First sale
- Jun 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$4.7MraisedNov 2023 · 1 investors · BiotechnologyRule 506(b)
▶$4.7MraisedNov 2023 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Adam J. ChillDirector
- Michael WeissDirector
- Manuel S. Litchman, M.D.Executive Officer, Director
- Lindsay A. Rosenwald, M.D.Director
- Michael Zelefsky, M.D.Director
- Neil HerskowitzDirector
- Eliot LurierExecutive Officer
- Offering amount
- $4.7M
- Amount sold
- $4.7M
- Sales commissions
- $308K
- Placement agents
- H.C. Wainwright & Co., LLC
- First sale
- Oct 2023
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$416KraisedApr 2017 · 7 investors · BiotechnologyRule 506(b)
▶$416KraisedApr 2017 · 7 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Michael S. WeissExecutive Officer, Director
- Neil HerskowitzDirector
- Lindsay A. RosenwaldDirector
- Offering amount
- $416K
- Amount sold
- $416K
- Sales commissions
- $45.6K
- Placement agents
- National Securities Corporation
- First sale
- Mar 2017
- Incorporated
- Corporation, Delaware, 2015
- Federal exemptions
- 06b
▶$94.6MraisedFeb 2017 · 1086 investors · BiotechnologyRule 506(b)
▶$94.6MraisedFeb 2017 · 1086 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Michael S. WeissExecutive Officer, Director
- Neil HerskowitzDirector
- Lindsay A. RosenwaldDirector
- Offering amount
- $100M
- Amount sold
- $94.6M
- Sales commissions
- $9.5M
- Placement agents
- National Securities Corporation
- First sale
- Jan 2017
- Incorporated
- Corporation, Delaware, 2015
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 4
by search overlap
Mammoth Biosciences29 shared keywordsMammoth Bio develops technology to read and write the code of life, operating in the biotechnology sector.
Robinhood26 shared keywordsRobinhood is a financial trading platform that enables users to manage portfolios across stocks, ETFs, cryptocurrencies, options, futures, and prediction markets. The platform serves retail investors with low barriers to entry, offering portfolio management services and market insights.
Seeking Alpha26 shared keywordsSeeking Alpha is a financial research platform offering stock analysis, market news, investment ideas, and quantitative ratings across asset classes, drawing on a large community of contributing analysts. It serves individual and professional investors seeking research and data-driven insight on stocks and markets.
TradingView23 shared keywordsTradingView is a charting platform and social network used by over 100 million traders and investors worldwide to analyze and trade across global financial markets. The platform provides tools for technical analysis, market data, and community collaboration for retail and institutional traders.
Companies competing with Mustang Bio for the same Google search keywords, organic and paid, via search-intersection analysis.
Frequently asked questions
- What does Mustang Bio do?
- Mustang Bio in-licenses and develops next-generation therapies aimed at treating patients, operating in the biotechnology and therapeutics sector.
- Who are Mustang Bio's investors?
- Mustang Bio's investors include Runway Growth Capital.
- How much funding has Mustang Bio raised?
- Mustang Bio has disclosed $102.3M raised across 4 rounds.
- Where is Mustang Bio headquartered?
- Mustang Bio is headquartered in Worcester, US.